The best Bull and Bear pitches based on recency and number of recommendations.
Durata has been very weak ahead of the dalbavancin NDA and MAA submissions despite what appears to be solid phase III data and the promise of priority NDA review due to QIDP status. Is the stock weak because no one talks about Durata, since Trius is… More
It's always difficult to reconstruct the history of a hand-me-down drug but in the case of Durata and dalbavancin, I've seen enough to discourage me from an investment. Dalbavancin is billed as a next-generation vancomycin, with the advantage of a… More
Read the most recent pitches from players about DRTX.DL.
Find the members with the highest scoring picks in DRTX.DL.
See what the Wall Street professionals think, according to their public statements and filings.